Neuroscience-Based Psychiatry: Rethinking Diagnosis for Psychedelic Therapies

Book Proposes Overhaul of Psychiatric Diagnosis for Brain-Based Therapies

A newly published book, Psychiatry: The Case for Starting Over (2026), contends that psychiatry’s reliance on symptom-based diagnosis—exemplified by the Diagnostic and Statistical Manual of Mental Disorders (DSM)—is fundamentally misaligned with advances in neuroscience and emerging circuit-targeted treatments, including psychedelic-assisted interventions. The author, drawing on computational modeling, systems neuroscience, and predictive processing theories, introduces a new framework: Neuroanalysis and Clinical Brain Profiling (CBP). This approach organizes mental disorders by disruptions in brain network dynamics and plasticity, aiming for a more mechanistic, biomarker-driven psychiatry.

Mechanism: Organizing Disorders by Brain Network Dynamics and Plasticity

Neuroanalysis and Clinical Brain Profiling (CBP) treat psychiatric disorders as disturbances in the organization and adaptability (plasticity) of large-scale brain networks, rather than as static symptom clusters. The book synthesizes three research lines: computational neural-network modeling (e.g., Hopfield, Hinton, Hoffman), systems neuroscience (large-scale networks, global workspace theory, attractor dynamics), and the Free Energy Principle (Karl Friston). The author proposes that mental disorders can be mapped across four timescales of brain plasticity:

• Cognizance plasticity (milliseconds): Central executive network, linked to psychosis and negative symptoms.
• Reactive plasticity (minutes to hours): Salience network, linked to anxiety disorders.
• Adaptive plasticity (days to weeks): Salience–default mode interface, linked to depression and mania.
• Developmental plasticity (lifetime): Default mode network, linked to personality disorders.

This framework enables the selection and sequencing of neuromodulatory interventions—including electroconvulsive therapy (ECT), deep brain stimulation (DBS), transcranial magnetic stimulation (TMS), transcranial electrical stimulation (tDCS/tACS), focused ultrasound, and psychedelic-assisted therapy—based on the targeted brain network and plasticity window. Notably, the book explicitly includes psychedelics as tools for opening plasticity windows, with the caveat that their use should be guided by continuous biomarker monitoring and prefrontal regulatory strengthening.

Policy, Research, and Clinical Implications

The proposed shift to Neuroanalysis and CBP has significant implications for research design, clinical trial endpoints, and regulatory frameworks. Moving away from consensus-based DSM categories toward measurement-based, mechanism-guided diagnosis could:

• Enable more precise patient stratification and personalized treatment selection in clinical trials, including those for psychedelic-assisted therapies.
• Facilitate the development and validation of network-based biomarkers as surrogate endpoints, potentially accelerating regulatory approval of novel interventions.
• Require a cultural and institutional shift in psychiatry, moving from single-label diagnoses to multidimensional brain profiling—a transition that could be as disruptive as the move from humoral theory to modern medicine.

One non-obvious implication is that clinical trials for psychedelics and other neuromodulators may need to incorporate dynamic brain network measures (such as functional MRI or EEG-based connectivity metrics) as both inclusion criteria and outcome measures. This would challenge current trial infrastructure and regulatory expectations, which are still largely built around symptom rating scales.

Risks, Unknowns, and Validation Challenges

Transitioning to a neuroscience-based diagnostic system presents substantial risks and unknowns. The book is explicit about the current lack of validated, clinically feasible network measures and the need for prospective outcome trials to test the proposed framework. Key challenges include:

• Measurement Feasibility: Most brain network metrics require advanced neuroimaging or electrophysiology, which are not yet standardized or widely available in clinical settings.
• Regulatory Acceptance: Agencies such as the U.S. Food and Drug Administration (FDA) and European Medicines Agency (EMA) have not yet endorsed network-based biomarkers as primary endpoints for psychiatric drug approval.
• Risk of Overfitting: Mechanism-based stratification could inadvertently exclude patients who do not fit neatly into network-defined categories, potentially reducing access or missing clinically meaningful heterogeneity.
• Ethical and Equity Concerns: Access to advanced neurodiagnostic tools may be limited by socioeconomic factors, raising concerns about equity in care and research participation.

Importantly, the book distinguishes between established science and theoretical proposals, underscoring that the Neuroanalysis framework remains to be validated in real-world clinical trials. The path to adoption will require not only technical advances but also shifts in training, reimbursement, and public understanding of mental health.

Outlook: Toward a Measurement-Based, Mechanism-Guided Psychiatry

The call to rebuild psychiatry as a measurement-based, mechanism-guided discipline—grounded in brain network science—could reshape the landscape for psychedelic research and clinical practice over the next decade. If adopted, frameworks like Clinical Brain Profiling may drive the next generation of clinical trials, regulatory submissions, and ultimately, patient care. However, realizing this vision will depend on the development of robust, accessible network biomarkers, the willingness of institutions to embrace multidimensional profiling, and the careful navigation of ethical and practical challenges. For now, the book serves as a provocative blueprint, inviting researchers, clinicians, and policymakers to reconsider the foundations of psychiatric diagnosis in the era of neuroscience and psychedelics.

How we research: This analysis was written and reviewed by Dr. Alex R. Bennett, PhD (neuroscience, policy editor), on 2026-10-02. Primary source: OpenAlex record W7214963252.